Chapter 3 Market and Technology Background
- Introduction
- Lung Cancer Types
- In Situ Lung Cancer
- Malignant Lung Tumors
- Stages of Lung Cancer
- Staging of NSCLC
- Staging of SCLC
- Risk Factors
- Tobacco Smoking
- Second-Hand Smoking (SHS)
- Exposure to Asbestos
- Exposure to Other Elements
- Family History
- Personal History
- Lung Cancer Symptoms
- Symptoms of Tumor Growth in the Lungs and Chest
- Symptoms Caused by Metastases Beyond the Chest
- Symptoms Caused by Tumor Secretion
- Lung Cancer Diagnosis
- General Screening Tests
- Lung Cancer Management
- Radiation Therapy
- Chemotherapy
- Surgery
- Targeted Therapy for Lung Cancer
- Immunotherapy for Lung Cancer
- Palliative Treatment for Lung Cancer
Chapter 4 Market Dynamics
- Market Drivers
- Global Increase in Lung Cancer Incidence
- Increase in Healthcare Expenditures and Government Funding in Key Countries
- Robust Clinical Drug Pipeline
- Increasing Life Expectancy of Lung Cancer Patients
- Surge in Female Smokers
- Market Restraints
- Patent Expiration of Key Drug Molecules
- Regulatory and Reimbursement Hurdles
- Available Low-Priced Chemotherapeutics Limiting Growth of Advanced Therapies
- Market Opportunities
- Highest Incidence of Lung Cancer in Asia-Pacific
- Increasing Demand for Targeted Therapies (EGFR or ALK Inhibitors, TKIs)
- Increasing Incidence of NSCLC and its Non-responsiveness to Chemotherapy
- Increasing Lung Cancer Incidence Among Non-Smokers
- Clinical Trial Failures
Chapter 5 Market Breakdown by Lung Cancer Type
- Market Overview
- Market Size and Forecast
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
Chapter 6 Market Breakdown by Region
- Epidemiology of Lung Cancer
- Global Market for Lung Cancer Therapeutics by Region
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South America
Chapter 7 Reimbursement Landscape
- Introduction
- United States
- Lung Cancer Drug Reimbursement
- Germany
- Lung Cancer Drug Reimbursement
- Brazil
- China
Chapter 9 Regulatory Landscape
- Regulatory Challenges for Lung Cancer Therapeutics
- North America
- United States
- Canada
- Mexico
- Europe
- Mutual Recognition Procedure
- Decentralized Procedure
- Centralized Procedure
- Asia-Pacific
- Japan
- China
- India
- South Korea
- Middle East and Africa
- Saudi Arabia
- South Africa
- South America
- Brazil
- Argentina
Chapter 10 Competitive Landscape
- Major Lung Cancer Drug Companies
- Eli Lilly and Co.
- AstraZeneca Pharmaceuticals
- Pfizer Inc.
Chapter 11 Pipeline Analysis
- Introduction
- Late-Stage Pipeline Drug Candidates
- JAK Inhibitors for Lung Cancer
- Third-Generation EGFR TKIs
Chapter 12 Company Profiles
- ABBVIE INC.
- Company Overview
- Financials
- Product Information
- Development and Strategies
- AMGEN INC.
- Company Overview
- ASTELLAS PHARMA INC.
- Financials
- ASTRAZENECA PLC
- Company Overview
- Financials
- Products and Services
- Developments and Strategies
- BAYER AG
- Company Overview
- Financials
- Product Information
- BETA PHARMA INC.
- Business Overview
- Products and Services
- BOEHRINGER INGELHEIM GMBH
- Company Overview
- Financials
- Products and Services
- Development and Strategies
- BRISTOL-MYERS SQUIBB CO.
- Company Overview
- Financials
- Products and Services
- CELGENE CORP.
- Company Overview
- Financials
- Products and Services
- DAIICHI SANKYO CO., LTD.
- Company Overview
- Financials
- Product and Services
- ELI LILLY AND CO.
- Company Overview
- Financials
- F. HOFFMANN-LA ROCHE AG
- Company Overview
- Financials
- Products and Services
- MERCK & CO., INC.
- Company Overview
- Financials
- Products and Services
- Development and Strategies
- NOVARTIS INTERNATIONAL AG
- Company Overview
- Financials
- Products and Services
- Development and Strategies
- PFIZER INC.
- Company Overview
- Financials
- Product Information
- Development and Strategies
- TAKEDA PHARMACEUTICALS CO.
- Company Overview
List of Tables
Summary Table: Global Market for Lung Cancer Therapeutics, by Type, Through 2023
Table 1: TNM Classification of Malignant Tumors of Lung Cancer
Table 2: Five-Year Survival Rates, NSCLC and SCLC
Table 3: Targeted Therapy for Lung Cancer
Table 4: Targeted Antibodies Used in Lung Cancer
Table 5: Immunomodulators Used in Lung Cancer
Table 6: CAR T-Cell Therapy Clinical Trials Under Investigation
Table 7: Comparison of Overall Estimated Number of New Cancer Cases, by Type, 2018
Table 8: Age-Standardized Lung Cancer Incidence Rate, Rankings by Country, 2017
Table 9: Age-Standardized Lung Cancer Incidence Rate in Men, Rankings by Country, 2017
Table 10: Age-Standardized Lung Cancer Incidence Rate in Women, Ranking by Country, 2017
Table 11: Lung Cancer Incidence in Key Countries, 2017
Table 12: Proportion of Daily Cigarette Smokers in Europe, by Gender, 2014
Table 13: Patent Expiration of Lung Cancer Drugs
Table 14: Incidence of Lung Cancer in Asia-Pacific, 2016
Table 15: Prominent Drugs to Treat Lung Cancer
Table 16: Global Market for Lung Cancer Therapeutics, by Type, Through 2023
Table 17: Global Market for Lung Cancer Therapeutics, by Region, Through 2023
Table 18: Estimated Lung Cancer Statistics for Canada, 2017
Table 19: Lung Cancer Incidence in Canada, Male and Female
Table 20: Overall Healthcare Expenditures in Europe, by Country, Through 2015
Table 21: Number of New Lung Cancer Cases in the U.K., by Gender, 2015
Table 22: Medicare Part B: Lung Cancer Drug Payment Limits, 2018
Table 23: Lung Cancer Drug Reimbursement in Germany, 2018
Table 24: Oncology Drugs Covered by China's National Insurance
Table 25: U.S. Patents on Lung Cancer Therapeutics, 2001-2018
Table 26: Patent Expiration of Lung Cancer Drugs
Table 27: List of FDA-Approved Drugs, Through 2018
Table 28: Lung Cancer Drugs Approved by Health Canada, Through 2018
Table 29: NSCLC Drugs Authorized by the EMA, Through 2018
Table 30: NSCLC Drugs Pending Approval by the EMA, Through 2018
Table 31: NSCLC Drugs Withdrawn by the EMA, Through 2018
Table 32: NSCLC Drugs Pending Application Withdrawal by the EMA, Through 2018
Table 33: SCLC Drugs Pending Withdrawal by the EMA, Through 2018
Table 34: Global Ranking of Lung Cancer Drug Companies, 2017
Table 35: Eli Lilly and Co.: Lung Cancer Marketed Products and Investigational Molecules, Through 2018
Table 36: AstraZeneca Pharmaceuticals: Lung Cancer Marketed Products and Investigational Molecules, Through 2018
Table 37: Lung Cancer Pipeline Drugs, Through 2018
Table 38: Clinical Efficacy of Select Third-Generation EGFR TKIs in Clinical Development
Table 39: AbbVie Inc.: Net Revenue, 2015-2017
Table 40: AbbVie Inc.: Lung Cancer Pipeline
Table 41: Astellas Pharma Inc.: Net Revenue, 2013-2017
Table 42: Astellas Pharma Inc.: Net Revenue, by Country/Region, 2014-2017
Table 43: AstraZeneca Plc: Net Revenue, 2014-2017
Table 44: AstraZeneca Plc: Marketed Products, 2018
Table 45: Bayer AG: Net Revenue, 2015-2017
Table 46: Bayer AG: Lung Cancer Pipeline Molecules
Table 47: Boehringer Ingelheim GmbH: Net Revenue, 2014-2016
Table 48: Boehringer Ingelheim GmbH: Marketed Product, 2018
Table 49: Bristol-Myers Squibb: Net Revenue, 2014-2016
Table 50: Bristol-Myers Squibb: Marketed Products, 2018
Table 51: Celgene Corp.: Net Revenue, 2015-2016
Table 52: Daiichi Sankyo Co., Ltd.: Net Revenue, 2015-2017
Table 53: Eli Lilly and Co.: Net Revenue, 2014-2017
Table 54: Eli Lilly and Co.: Net Revenue, by Segment, 2014-2016
Table 55: Eli Lilly and Co.: Net Revenue, by Oncology Drug, 2014-2016
Table 56: F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, Through 2017
Table 57: Tarceva: Drug Revenue, by Country/Region, 2016-2017
Table 58: Merck & Co., Inc.: Net Revenue, 2014-2016
Table 59: Novartis International AG: Net Revenue, by Segment, Through 2017
Table 60: Novartis International AG: Oncology Drugs Revenue, 2015-2017
Table 61: Pfizer Inc.: Net Revenue, 2014-2017
Table 62: Pfizer Inc.: Oncology Drug Revenue, 2015-2017
Table 63: Pfizer Inc.: Oncology Drugs Revenue, 2015-2017
Table 64: Pfizer Inc.: Lung Cancer Marketed Products and Investigational Drug Candidates, 2018
Table 65: Acronyms Used in Global Lung Cancer Therapeutics Market
List of Figures
Summary Figure: Global Market for Lung Cancer Therapeutics, by Type, 2017-2023
Figure 1: Gross Anatomy of the Human Lung
Figure 2: Share of Lung Cancer Types, by Histology
Figure 3: National Cancer Institute Research Funding, 2011-2016
Figure 4: U.S. Smoking Statistics, by Gender, 2017
Figure 5: Percentage Share of Lung Cancer Incidence, by Type of Mutation
Figure 6: Global Market for Non-Small Cell Lung Cancer Therapeutics, 2017-2023
Figure 7: Global Market for Small Cell Lung Cancer Therapeutics, 2017-2023
Figure 8: Percentage Share of Global Lung Cancer Incidence, by Country/Region, 2018
Figure 9: North American Market for Lung Cancer Therapeutics, 2017-2023
Figure 10: Percentage Share of Estimated Cancer Incidence in North America, by Type, 2018
Figure 11: Percentage Share of Estimated Cancer Incidence in the United States, by Type, 2018
Figure 12: European Market for Lung Cancer Therapeutics, 2017-2023
Figure 13: Per Capita Spending on Market Sectors in Europe, 2015
Figure 14: Incidence Rates of Lung Cancer in the U.K., by Gender, 1993-2015
Figure 15: Incidence of Lung Cancer in Scotland, by Cancer Stage, 2014-2015
Figure 16: Incidence of Lung Cancer in Italy, by Gender, 2010 and 2015
Figure 17: Percentage Share of Estimated Cancer Incidence in France, by Type, 2018
Figure 18: Percentage Share of Estimated Cancer Incidence in Germany, by Type, 2018
Figure 19: Asia-Pacific Market for Lung Cancer Therapeutics, 2017-2023
Figure 20: Percentage Share of Estimated Cancer Incidence in Asia-Pacific, by Type, 2018
Figure 21: Estimated Cancer Incidence in Asia-Pacific, by Country, 2018
Figure 22: Middle East and African Market for Lung Cancer Therapeutics, 2017-2023
Figure 23: Percentage Share of Estimated Cancer Incidence in Africa, by Type, 2018
Figure 24: South American Market for Lung Cancer Therapeutics, 2017-2023
Figure 25: Percentage Share of Estimated Cancer Incidence in South America, by Type, 2018
Figure 26: Drug Reimbursement Scenerio in Germany
Figure 27: Federal and Inter-Provincial Approval System for Cancer Drugs in Canada
Figure 28: Medical Device PMDA Approval Procedure
Figure 29: AbbVie Inc.: Revenue Share, by Region, 2016
Figure 30: Erlotinib: Revenue, 2015-2016
Figure 31: AstraZeneca Plc: Financial Performance, 2015-2017
Figure 32: AstraZeneca Plc: Financial Performance, 2013-2017
Figure 33: AstraZeneca Plc: Revenue Share, by Business Unit, 2017
Figure 34: AstraZeneca Plc: Revenue Share, by Country/Region, 2017
Figure 35: Bayer AG: Revenue Share, by Region, 2017
Figure 36: Bayer AG: Revenue Share, by Region, 2017
Figure 37: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2016
Figure 38: Boehringer Ingelheim GmbH: Revenue Share, by Business Segment, 2016
Figure 39: Boehringer Ingelheim GmbH: Research and Development Expenditures, 2014-2016
Figure 40: Bristol-Myers Squibb: Revenue Share, by Country/Region, 2016
Figure 41: Bristol-Myers Squibb: Revenue Share, by Business Segment, 2016
Figure 42: Abraxane: Revenue, 2015-2017
Figure 43: Daiichi Sankyo Co., Ltd.: Revenue Share, by Business Segment, 2016
Figure 44: Eli Lilly and Co.: Revenue Share, by Country/Region, 2016
Figure 45: F. Hoffmann-La Roche Ltd.: Pharmaceuticals Revenue Share, by Business Segment, 2016
Figure 46: F. Hoffmann-La Roche Ltd.: Lung Cancer Drug Revenue, 2016-2017
Figure 47: Merck & Co., Inc.: Revenue Share, by Business Segment, 2016
Figure 48: Merck & Co., Inc.: Keytruda Revenue, 2015-2017
Figure 49: Merck & Co., Inc.: Revenue Share, by Region, 2016
Figure 50: Pfizer Inc.: Revenue Share, by Region, 2016
Figure 51: Pfizer Inc.: Revenue Share, by Business Segment, 2016
